Cart
sales@molnova.com
Ozagrel
CAS No. 82571-53-7
Ozagrel( OKY-046 )
Catalog No. M16065 CAS No. 82571-53-7
Ozagrel is a selective thromboxane A(2) (TXA(2)) synthetase inhibitor with IC50 of 11 nM for rabbit platelet.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 29 | In Stock |
|
| 10MG | 37 | In Stock |
|
| 25MG | 67 | In Stock |
|
| 50MG | 100 | In Stock |
|
| 100MG | 152 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 368 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameOzagrel
-
NoteResearch use only, not for human use.
-
Brief DescriptionOzagrel is a selective thromboxane A(2) (TXA(2)) synthetase inhibitor with IC50 of 11 nM for rabbit platelet.
-
DescriptionOzagrel is a selective thromboxane A(2) (TXA(2)) synthetase inhibitor with IC50 of 11 nM for rabbit platelet, used for the improvement of postoperative cerebrovascular contraction and accompanying cerebral ischaemia.
-
In Vitro——
-
In Vivo——
-
SynonymsOKY-046
-
PathwayAutophagy
-
TargetThrombin
-
RecptorThromboxane A2 synthetase
-
Research AreaCardiovascular Disease
-
Indication——
Chemical Information
-
CAS Number82571-53-7
-
Formula Weight228.25
-
Molecular FormulaC13H12N2O2
-
Purity>98% (HPLC)
-
SolubilityDMSO: 46 mg/mL (201.53 mM)
-
SMILESC1=CC(=CC=C1CN2C=CN=C2)/C=C/C(=O)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ishitsuka Y, et al. J Pharmacol Sci, 2009, 111(2), 211-215.
molnova catalog
related products
-
Ximelagatran
Ximelagatran, a direct thrombin inhibitor, can be taken orally and acts solely by inhibiting the actions of thrombin. Ximelagatran is converted to the active agent melagatran in vivo.
-
AZD-0837
AZD-0837 is a novel oral anticoagulant that after bioconversion to its active form is a potent and reversible thrombin inhibitor.
-
AZD-8165
AZD-8165 is a potent, selective and oral thrombin inhibitor for treatment of thrombosis.
